CRL
Charles River Laboratories
NYSE: CRL · HEALTHCARE · DIAGNOSTICS & RESEARCH
$168.46
-2.40% today
Updated 2026-06-05
Market cap
$9.03B
P/E ratio
—
P/S ratio
2.24x
EPS (TTM)
$-3.71
Dividend yield
—
52W range
$143 – $229
Volume
0.9M
WallStSmart proprietary scores
43
out of 100
Grade: D
Sell
Investment rating
3.3
Growth
D4.5
Quality
C4.5
Profitability
C6.3
Valuation
B4/9
Piotroski F-Score
Moderate
1.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$212.27
+26.01%
12-Month target
—
—
Intrinsic (DCF)
$161.89
Margin of safety
-2.53%
3 Strong Buy10 Buy3 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Altman Z 1.38 — distress zone
- Thin margins at -4.59%
- Negative free cash flow $-14.83M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $3.98B | $4.13B | $4.05B | $4.02B | $4.03B |
| Net income | $486.23M | $474.62M | $10.30M | $-144.34M | $-14.84M |
| EPS | — | — | — | — | $-3.71 |
| Free cash flow | $294.91M | $365.37M | $501.61M | $518.49M | $-14.83M |
| Profit margin | 12.23% | 11.49% | 0.25% | -3.59% | -4.59% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| — | ACKERMAN, THOMAS F | Sale | 16,000 | $31.35 |
| 2026-06-05 | PARISOTTO, SHANNON M | Sale | 1,529 | — |
| 2026-06-05 | GIRSHICK, BIRGIT | Sale | 3,386 | — |
Peer comparison
Smart narrative
Charles River Laboratories trades at $168.46. Our Smart Value Score of 43/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 1.38, it sits in the distress. TTM revenue stands at $4.03B. with profit margins at -4.59%. Our DCF model estimates intrinsic value at $161.89.
Frequently asked questions
What is Charles River Laboratories's stock price?
Charles River Laboratories (CRL) trades at $168.46, on a P/S of 2.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Charles River Laboratories overvalued?
Charles River Laboratories carries a Smart Value Score of 43/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $161.89 against the $168.46 price, so on cash flow terms the market is paying a premium for Charles River Laboratories's growth. The Sell rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Charles River Laboratories (CRL)?
The 12-month analyst consensus target is $212.27, about 26.0% above the current $168.46. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Charles River Laboratories (CRL)?
Our DCF model estimates intrinsic value at $161.89, a -2.5% margin of safety versus today's $168.46. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Charles River Laboratories's revenue?
Charles River Laboratories's trailing twelve-month revenue is $4.03B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Charles River Laboratories's Altman Z-Score is 1.38, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio2.24x
ROE-6.28%
Beta1.45
50D MA$173.48
200D MA$177.56
Shares out0.05B
Float0.05B
Short ratio—
Avg volume0.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—